Get the Stockscreener App
69.27
3.52%
-2.53
Monopar Therapeutics Inc stock is traded at $69.27, with a volume of 142.40K.
It is down -3.52% in the last 24 hours and down -31.72% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
See More
Previous Close:
$71.80
Open:
$71.01
24h Volume:
142.40K
Relative Volume:
0.86
Market Cap:
$464.95M
Revenue:
Net Income/Loss:
$-14.99M
P/E Ratio:
-33.52
EPS:
-2.0665
Net Cash Flow:
$-10.01M
1W Performance:
-12.27%
1M Performance:
-31.72%
6M Performance:
+20.05%
1Y Performance:
-16.10%
1-Day Range:
$68.81
$71.01
1-Week Range:
$68.81
$79.59
52-Week Range:
$50.07
$124.82
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
69.27 | 464.95M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-09-26 | Initiated | Morgan Stanley | Overweight |
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Form 4 Monopar Therapeutics Inc: Andrew Cittadine (COO) For: 30 September - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc: Chandler Robinson (Director, CEO) For: 30 September - Investing.com India
Form 4 Monopar Therapeutics Inc: Quan Anh Vu (CFO) For: 30 September - Investing.com Canada
Monopar Therapeutics director Christopher Starr sells shares worth $659k By Investing.com - Investing.com Canada
Form 4 Monopar Therapeutics Inc For: 11 October By Investing.com - Investing.com Canada
Monopar Therapeutics stock faces insider selling after Q2 loss - AD HOC NEWS
Form 4 Monopar Therapeutics Inc For: 6 October By Investing.com - Investing.com Canada
After a $0.005-per-share option exercise, Monopar Therapeutics (MNPR) director sells 8,400 shares. - Stock Titan
180 shares cover CFO taxes as Monopar Therapeutics (MNPR) settles a 614-share stock grant. - Stock Titan
16,800 shares are proposed for sale by Monopar Therapeutics (MNPR) director Christopher Starr. - Stock Titan
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com South Africa
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com India
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com Canada
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com UK
Four share sales at $87.15 to $89.79: Monopar Therapeutics (MNPR) CEO also exercised options. - Stock Titan
Stock-option shares are proposed for sale by Chandler Robinson at Monopar Therapeutics (NASDAQ: MNPR). - Stock Titan
Monopar Therapeutics Is Maintained at Overweight by Barclays - Moomoo
MNPR Maintained by Barclays -- Price Target Raised to $145 - GuruFocus
Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $145 - Moomoo
Discipline and Rules-Based Execution in MNPR Response - Stock Traders Daily
Monopar Therapeutics shares technical analysis: $120.21 resistance in focus after rally - Traders Union
Monopar Therapeutics stock trades near record levels as investors react to insider selling and stron - ad-hoc-news.de
What's behind Monopar Therapeutics's latest 3.0% stock pullback? - Traders Union
Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares By Investing.com - Investing.com Canada
Monopar Therapeutics (MNPR) director sells 4,090 shares after option exercises - Stock Titan
Monopar Therapeutics director Raymond Anderson sells $351,835 in stock By Investing.com - Investing.com Canada
Monopar (MNPR) insider sells at $110–113 after $30 option exercise - stocktitan.net
Will Monopar Therapeutics stock regain momentum as oversold conditions limit further selling? - Traders Union
Monopar Therapeutics director Raymond Anderson sells $351,835 in stock - Investing.com
Monopar director Kim Tsuchimoto sells $455k in common stock - Investing.com India
Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares - Investing.com
Monopar director Kim Tsuchimoto sells $455k in common stock By Investing.com - Investing.com Nigeria
Monopar Therapeutics director Raymond Anderson sells $351k in stock By Investing.com - Investing.com Canada
Monopar Therapeutics Director Kim R. Tsuchimoto Executes Six-Tranche Stock Sale Under Rule 10b5-1 Plan - Kalkine Media
Monopar Therapeutics (MNPR) CMO uses plan to exercise options - stocktitan.net
Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares - Bitget
Monopar Therapeutics (MNPR) director sells 3,142 shares in plan trade - stocktitan.net
Monopar Therapeutics acting CMO sells $111 of stock, exercises options - Investing.com
Monopar Therapeutics (MNPR) director sells 4,090 shares near $110 - Stock Titan
Monopar Therapeutics (MNPR) director plans $906K share sale - Stock Titan
Monopar Therapeutics stock resistance test: Key levels to watch - tradersunion.com
Monopar Therapeutics (MNPR) acting CMO plans 1-share sale - Stock Titan
Monopar (NASDAQ: MNPR) director to sell 6,284 shares - Stock Titan
Companies Like Monopar Therapeutics (NASDAQ:MNPR) Can Afford To Invest In Growth - webull.com
Monopar (MNPR) Quarter in Focus: EPS Clears the Reported Estimate in the Current Update; Trading Response: Shares Close 2.85% Lower in the Latest SessionForward EPS Estimate - vinanet.vn
Monopar (MNPR) Quarter in Focus: EPS Clears the Reported Estimate in the Current Update; Trading Response: Shares Close 2.85% Lower in the Latest SessionInvestor Earnings Call - vinanet.vn
Monopar (MNPR) Latest: Ends Lower by 2.85% at $107.72 in the Latest Reading; Technical Setup: Price Remains Between $102.33 Support and $113.11 Resistance at the CloseBreak of Structure - vinanet.vn
MNPR drops as short-term selling pressure persists - Traders Union
What's behind Monopar Therapeutics's latest stock pullback? - Traders Union
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STARR CHRISTOPHER M | Director |
Oct 01 '26 |
Sale |
78.50 |
8,400 |
659,387 |
5,173 |
| CHRISTOPHER STARR | Director |
Oct 01 '26 |
Proposed Sale |
79.67 |
16,800 |
1,338,456 |
0 |
| Robinson Chandler | Chief Executive Officer |
Sep 24 '26 |
Option Exercise |
21.74 |
29,056 |
631,680 |
128,323 |
| CHANDLER ROBINSON | Director |
Sep 24 '26 |
Proposed Sale |
89.38 |
29,056 |
2,597,025 |
0 |
| Robinson Chandler | Chief Executive Officer |
Sep 24 '26 |
Sale |
88.00 |
29,056 |
2,556,851 |
99,267 |
| RIOUX PATRICE | Acting Chief Medical Officer |
Aug 26 '26 |
Sale |
111.26 |
1 |
111 |
5,065 |
| Tsuchimoto Kim R | Director |
Aug 26 '26 |
Sale |
111.39 |
4,090 |
455,567 |
7,396 |
| PATRICE RIOUX | Acting Chief Medical Officer |
Aug 26 '26 |
Proposed Sale |
110.82 |
1 |
111 |
0 |
| KIM TSUCHIMOTO | Director |
Aug 26 '26 |
Proposed Sale |
110.82 |
8,180 |
906,508 |
0 |
| RIOUX PATRICE | Acting Chief Medical Officer |
Aug 26 '26 |
Option Exercise |
0.01 |
1,380 |
7 |
5,066 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):